From owner-repertoires@net.bio.net Thu Jan 09 22:00:00 1997 Newsgroups: bionet.molecules.repertoires Path: biosci!fcs280s.ncifcrf.gov!cpk-news-feed1.bbnplanet.com!news.bbnplanet.com!cpk-news-hub1.bbnplanet.com!EU.net!uknet!usenet1.news.uk.psi.net!uknet!uknet!bcc.ac.uk!news From: zctpm92@ucl.ac.uk Subject: Academic Research Survey Message-ID: <1997Jan10.210239.39824@ucl.ac.uk> Date: Fri, 10 Jan 1997 21:02:39 GMT Content-Transfer-Encoding: 7bit Content-Type: text/plain; charset=us-ascii Mime-Version: 1.0 X-Mailer: Mozilla 1.22 (Windows; I; 16bit) Organization: University College London Lines: 237 Hello. I am a final year undergraduate student at University College London, University of London, England. This questionnaire is my means of collecting data for a geographical analysis of the Internet - with particular reference to meeting and communicating via the Internet. It is aimed at users of newsgroups and e-mail. Your newsgroup was selected randomly. If you would complete the questionnaire it would be much appreciated. I assure you that all information will be kept confidential and will only be used for academic research. I will be ready to accept responses until the 27TH OF JANUARY 1997. Please respond by i. typing an 'x' (for answers with dots to the left hand side) or your written response (for answers with dots to the right hand side) - in each case please fill in only ONE option - and E-MAILING THE SURVEY back to me. OR ii. E-MAILING ME JUST YOUR ANSWERS: type the question number and the letter of your chosen response (for answers with dots to the left hand side) or the question number and your written response (for answers with dots to the right hand side) - in each case please fill in only ONE option. My e-mail address is ZCTPM92@UCL.AC.UK Thank you. THE INTERNET IN GENERAL (QUESTIONS 1 TO 3) 1. Where is the principal computer you use to access the Internet located? a. ..... Office b. ..... Home c. ..... School/College/University d. ..... Cybercafe e. Other (please specify) ..... 2. How long do you spend using EACH of the following parts of the Internet (including off-line reader in each case e.g. Eudora)? i. e-mail - hours per week ..... ii. newsgroups - hours per week ..... iii. World Wide Web - hours per week ..... iv. Internet Relay Chat - hours per week ..... v. other - hours per week ..... 3. Do you use the Internet MORE for a. ..... accessing information b ..... communicating with people E-MAIL (including off-line reader e.g. Eudora) EXCLUDING INTERACTIONS IN NEWSGROUPS (QUESTIONS 4 TO 13) 4. How long have you been using e-mail? ..... 5. Of the people you communicate with via e-mail, are the MAJORITY: a. ..... people you knew BEFORE you started using e-mail b. ..... people you have become friendly with AS A RESULT of using the Internet 6. Has your use of e-mail: a. ..... NOT CHANGED the amount you move from one place to another in the real world b. ..... REDUCED the amount you move from one place to another in the real world c. ..... INCREASED the amount you move from one place to another in the real world 7. If you answered (b) reduced OR (c) increased above, could you please give an example ..... 8. If you use e-mail for WORK/STUDY activities, are you communicating MOSTLY with: a. ..... people working in the SAME BUILDING b. ..... people working TEMPORARILY AWAY FROM THE OFFICE c. ..... people who WORK FROM HOME d. ..... people who work ABROAD permanently e. other (please specify) ..... 9. If you use e-mail for WORK/STUDY activities, what PERCENTAGE of the total time you spend communicating IN GENERAL (letters, telephone, meeting up with people etc) is spent communicating via e-mail % ..... 10. If you use e-mail for NON-WORK/STUDY activities, are you communicating MOSTLY with: a. ..... people in the SAME BUILDING b. ..... people within the SAME TOWN/CITY c. ..... people in the SAME COUNTRY d. ..... people ABROAD e. other (please specify) ..... 11. If you use e-mail for NON-WORK/STUDY activities, what PERCENTAGE of the total time you spend communicating IN GENERAL (letters, telephone, meeting up with people etc) is spent communicating via e-mail % ..... 12. Do you use e-mail MORE for: a. ..... work activities b. ..... non-work activities c. ..... neither, about the same 13. How seriously do you take your interactions via E-MAIL? a. ..... extremely seriously b. ..... very seriously c. ..... seriously d. ..... not very seriously e. ..... not at all seriously NEWSGROUPS IN GENERAL (QUESTIONS 14 TO 19) 14. How many newsgroups do you use? ..... 15. Do the people you communicate with in your newsgroup(s) FEEL to you, as REAL as the people you communicate with in the REAL world: a. Yes, because ..... b. No, because ..... 16. Have you ever met any members of the newsgroup(s) you belong to? a. Yes, for the purpose of ..... b. ..... No, but I would like to c. No, because ..... 17. On the whole do you think anonymity is a. ..... a positive feature of newsgroups b. ..... a negative feature of newsgroups 18. In theory would you PREFER audio-visual postings in newsgroups to text-based one? a. Yes, because ..... b. No, because ..... 19. Do your newsgroup interactions make you feel any more than usual a part of a GLOBAL/WORLDWIDE community? a. ..... Yes b. ..... No FOR THIS SECTION (QUESTIONS 20 TO 24) PLEASE SELECT ONE NEWSGROUP YOU BELONG TO AND ANSWER THE QUESTIONS WITH REFERENCE TO IT 20. What is the address of this group? ..... 21. Does the newsgroup have a focus in any country/region? a. Yes, it is focused in ..... b. ..... No. 22. In what countries do the members of your newsgroup live (as many as you can give)? ..... 23. In what country does the most distant person YOU talk to live? ..... 24. What do you gain from subscribing to this newsgroup? ..... MISCELLANEOUS (QUESTIONS 25 AND 26) 25. How seriously do you take your interactions in NEWSGROUPS? a. ..... extremely seriously b. ..... very seriously c. ..... seriously d. ..... not very seriously e. ..... not at all seriously 26. Would it be right to say you have become friendly with more people as a result of using newsgroups, than by using ANY OTHER PART OF THE INTERNET a. ..... Yes b. ..... No, I have met AS MANY via Internet Relay Chat groups c. ..... No, I have met AS MANY via e-mail addresses attached to web sites d. No, I have met AS MANY via (please specify) ..... 27. Where did you access this questionnaire? ..... CYBERSPACE (QUESTION 28 AND 30) 28. In your opinion, what/where is cyberspace? ..... 29. How is the Internet related to cyberspace? ..... 30. Do you think cyberspace could be mapped? a. Yes, because ..... b. No, because ..... PERSONAL INFORMATION (QUESTIONS 31 TO 36) 31. What age group are you in? a. ..... Under 13 b. ..... 13-16 c. ..... 17-20 d. ..... 21-30 e. ..... 31-50 f. ..... 51+ 32. Are you: a. ..... Male b. ..... Female 33. What country are you in when you use the Internet? ..... 34. Are you currently: a. ..... Student b. ..... Unemployed c. ..... Working full/part time OUTSIDE THE HOME d. ..... Working full/part time FROM THE HOME e. ..... Retired f. ..... Other (please specify) 35. If you are employed, what is your occupation? ..... 36. How long have you been using computers? ..... 37. IF YOU HAVE ANY OTHER COMMENTS PLEASE INCLUDE THEM HERE: ..... From owner-repertoires@net.bio.net Thu Jan 09 22:00:00 1997 Path: biosci!qub.ac.uk!a.wallace From: a.wallace@qub.ac.uk (Andrew Wallace) Newsgroups: bionet.molecules.repertoires Subject: Molreps FAQ for January 1997 Date: 10 Jan 1997 04:06:56 -0800 Organization: Queens University Belfast Lines: 256 Sender: daemon@net.bio.net Distribution: world Message-ID: <32D6315E.5B1E@qub.ac.uk> Reply-To: a.wallace@queens-belfast.ac.uk NNTP-Posting-Host: net.bio.net M O L R E P S F R E Q U E N T L Y A S K E D Q U E S T I O N S ********** ************** ******* ************* **1 Where can I obtain libraries?** 1.1 _Phage Libraries_ You can try approaching the following people and organisations: 1.1.1 pIII/6-mer, pIII/15-mer, pVIII-4/15-mer libraries: George Smith, University of Missouri, FAX +1-573-882-0123 1.1.2 pVIII/9-mer, pVIII/9-merCys and pVIII/zinc-finger phagemid libraries: Alessandra Luzzago, IRBM P. Angeletti, luzzago@irbm.it Franco Felici, IRBM P. Angeletti, felici@irbm.it (NON-COMMERCIAL USERS ONLY) 1.1.3 Antibody scFvs with synthetic CDRs: Greg Winter, MRC-LMB Cambridge, gw@mrc-lmb.cam.ac.uk Contact Fiona Sait at fs1@mrc-lmb.cam.ac.uk (NON-COMMERCIAL USERS ONLY) 1.1.4 Commercial Sources: Stratagene (Fab fragments in phage lambda) Affymax Pharmacia Cambridge Antibody Technology New England Biolabs (pIII/7-mer). (NEB catalog, p.166). see also this URL -> http://vent.neb.com/neb/phd/phd.html pSKAN Phagemid Display System from MoBiTec via NBL (+44-1670) 733015 EZtrap Phage Display cDNA libraries-AMS Biotechnology (+44-1993) 706500 1.2 _Synthetic Peptide Libraries_ 1.2.1 Commercial Sources: Affymax Chiron Corporation Most of the major peptide companies will custom-synthesise a library to your requirements. 1.3 _Nucleic Acid Libraries_ (Aptamers) 1.3.1 Jack Szostak at Harvard medical school? 1.3.2 NEXUS corporation (Larry Gold)? 1.4 _Organic Chemical Libraries_ 1.4.1 Affymax? 1.4.2 Parke-Davis (DIVERSOMERS)? **2) Where can I get anti-phage antibodies?** 2.1 anti-pIII MAb from Michael Tesar mte@gbf-braunschweig.de 2.2 anti-pIII polyclonals from GATC, a German company, FAX +49-7531-57313 TEL +49-7531-57204 2.3 rabbit anti-M13 from Stratagene. 2.4 sheep anti M13 phage sheep anti M13 phage biotinylated 5 Prime - 3 Prime Boulder CO (800)533-5703 **3) How can I make my own libraries?** 3.1 _Phage Libraries_ You can obtain suitable vectors and strains from most of the sources in 1). For phagemid work you can buy XL-1 Blue cells from Stratagene and M13K07 helper phage from Pharmacia. 3.2 _Synthetic Peptide Libraries_ 3.2.1 Manual synthesis Houghten's "Tea Bag" method Geysen's "Pin" method MULTIBLOCK method - see http://www.azstarnet.com/~mlebl Any of these can be adapted to produce either support-bound or soluble libraries. 3.2.2 Automated synthesis Chiron Corporation (Zuckermann) Advanced Chemtech (Commercial robot for 75K sterling) 3.3 _Nucleic Acid Libraries_ 3.3.1 PCR methods 3.4 _Organic Chemical Libraries_ 3.4.1 Manual synthesis 3.4.2 Automated synthesis (Advanced Chemtech) **4) How can I analyse the results of my selection?** 4.1 Insert sequencing (phage libraries) 4.2 Micropanning (Smith and Scott, Methods Enzymol. (1993) 217:228-257) 4.3 Dot-blotting (Felici et al., J. Mol. Biol. (1991) 222:301-310) 4.4 ELISA (Smith and Scott, Methods Enzymol. (1993) 217:228-257) (Dente et al. Gene (1994) 148:7-13) 4.5 Colony immunoscreening (Christian et al. J. Mol. Biol. (1992) 227, 711-718) (Felici et al. Gene (1993) 128, 21-27) 4.5 Plaque immunoscreening (Luzzago et al., Gene (1993) 128:51-57) (Felici et al., Methods Enzymol. (1996) 267:116-129) **5) Are there any World Wide Web (WWW) sites about molreps?** 5.1 http://www.bio.net/ - The BIOSCI web site itself (MOLREPS message archive) 5.2 http://bionmr1.rug.ac.be/chemistry/overview.html - A useful chemistry site 5.3 http://vesta.pd.com/ - Site for the journal MOLECULAR DIVERSITY 5.4 http://www.mrc-cpe.cam.ac.uk/imt-doc/vbase-home-page.html - Immunoglobulin v-gene database 5.5 http://molbio.info.nih.gov/molbio/desk.html - Molecular biologists desk reference 5.6 http://www.Kairos-scientific.com/ - Kairos scientific home page 5.7 http://www-lmmb.ncifcrf.gov/~toms/sequencelogo.html - Tom Schneider's Sequence Logo 5.8 http://www.ebi.ac.uk/ - The European Bioinformatics Institute (EBI) 5.9 http://www.ebi.ac.uk/primers_home.html - PCR primers database at EBI 5.10 http://aminoacid.bri.nrc.ca:1125/ - Database of building blocks for library synthesis 5.11 http://vent.neb.com/neb/phd/phd.html - PHD phage library at New England Biolabs 5.12 ftp://ftp.netcom.com/pub/qu/quincicc/maxim.html - Another library source 5.13 http://www.ebi.ac.uk/imgt/ - Database of genes of immunological importance 5.14 http://immuno.bme.nwu.edu/ - Kabat database of proteins of immunological interest **6) Do phage absorb non-specifically to ELISA plates?** Yes, use MaxiSorp plates for best binding. Answer by: Pascal Mertens Laboratoire d'Immunologie et Microbiologie URBM-FUNDP 61 Rue de Bruxelles 5000 Namur, BELGIUM From owner-repertoires@net.bio.net Wed Jan 15 22:00:00 1997 Path: biosci!daresbury!not-for-mail From: Andrew Wallace Newsgroups: bionet.molecules.repertoires Subject: Molecular Diversity Conferences Date: 16 Jan 1997 20:07:16 -0000 Lines: 202 Sender: lpddist@mserv1.dl.ac.uk Distribution: bionet Message-ID: <5bm1pk$pmv@mserv1.dl.ac.uk> Original-Sender: awallace@uk.ac.qub MIME-Version: 1.0 X-Authentication: none Read-Receipt-To: Andrew Wallace Original-To: molreps@dl.ac.uk The Cambridge Healthtech Institute has three upcoming conferences =0Athat w= ould be of interest to the subscribers of molreps.=0AI have listed below th= e conference program for each. If you wish to =0Ahave more information plea= se contac:=0A=0ACambridge Healthtech Institute=0A1037 Chestnut Street=0ANew= ton Upper Falls, MA 02164=0A=0APhone:617-630-1300=0AFax: 617-630-1325=0Ae-= mail:chi@healthtech.com=0Ahttp://www.healthtech.com/conferences/=0A=0ACambr= idge Healthtech Institute Fourth Annual =0AExploiting Molecular Diversity: = Small Molecule Libraries for Drug Discovery=0AFebruary 3-5, 1997 * Loews C= oronado Bay Resort, Coronado, CA=0A=0ACURRENT AND FUTURE BUSINESS/COMMERCIA= L APPLICATIONS=0ABusiness Issues in Combinatorial Drug Discovery: =0AMr. D= avid K. Stone, Cowen & Co. (confirmed)=0ACreating Exclusively in Molecular = Diversity--Patent Law: =0AMr. John W. Caldwell, Woodcock Washburn Kurtz Ma= ckiewicz & Norris (confirmed)=0ACombinatorial Chemistry Driving Biology : = A High-Throughput System to=0ADiscover Lead Drugs and Drug Target Genes: = =0ADr. Tauseef R. Butt (confirmed)=0AMolecular Diagnostics, Molecular Pheno= types, and Therapy Targeting: Impacts=0Aon Discovery: =09=0ADr. Christopher= A. Fields, National Center for Genome Resources (confirmed)=0AHigh-Through= put Lead Follow-up and Explosion: The Next Step in the Drug=0ADiscovery Pi= peline: =0ADr. Cheryl D. Garr, Panlabs, Inc. (confirmed)=0A=0AINFORMATICS= =0AIntegrating Mixtures and Libraries into High-Throughput Screening Data= =0AHandling and Analysis: =0ADr. Barr E. Bauer, MDL Information Systems, I= nc. (confirmed)=0ARole of 3D Information in the Combinatorial Chemistry Pro= cess: Library=0ADesign, Analysis, and SAR: =0ADr. Scott D. Kahn, Molecula= r Simulations, Inc. (confirmed)=0ADesigning Chemical Libraries for Lead Fin= ding and Lead Following: =0ADr. Allan M. Ferguson, Tripos, Inc. (confirmed= )=0AThe Well Tailored Library: Beyond Mere Diversity: =0ADr. Eric Martin,= Chiron Corporation (confirmed)=0ATitle to be Announced: Dr. Joseph Hogan,= ArQule, Inc. (confirmed)=0A=0ALIBRARY STRATEGIES=0ARecent Advances in the = Synthesis and Screening of Small Molecule Libraries=0Ain Solution: =0ADr. = Edward A. Wintner, MIT (confirmed)=0AVersatility and Advantages of Random a= nd Directed Libraries Constructed as=0ASingle Compound, Solution Phase Reac= tions: =0ADr. James Rusche, Repligen Corporation (confirmed)=0ACombinatori= al Development Profiling: =0ADr. Robyn A. Rourick, Bristol-Myers Squibb (c= onfirmed)=0ASolution Phase, Simultaneous Addition of Functionalities (SPSAF= ) for the=0AGeneration of Combinatorial Chemistry Libraries: =0ADr. P. Dan= Cook, Isis Pharmaceuticals (confirmed)=0AEncoded Combinatorial Libraries: = =0ADr. H. Mario Geysen, Glaxo Wellcome, Inc. (confirmed)=0ACombinatorial C= hemistry: From Concept to Application as a Drug Discovery Tool: =0ADr. Ale= x Polinsky, Alanex Corp. (confirmed)=0AUse of Reactive Fragment Structure T= ransformations for Automated Structure=0AGeneration and Applications to Div= ersity Analysis in Combinatorial Chemistry: =0ADr. John F. Cargill, Ontogen= Corp. (confirmed)=0AUse of a Hetero Diels-Alder Reaction to Prepare Tricyclic Quinolines: =0ADr. John S. Kiely, Houghten Pharmaceutica= ls, Inc. (confirmed)=0ALow Diversity SMART LIBRARY=99 Constrained Secondary= Structure Templates for=0Athe Development of Small Molecule Mimetics: =0A= Dr. Michael Kahn, Molecumetics, Inc. (confirmed)=0ACombinatorial Genomics a= nd Small Molecule Drug Discovery: =0ADr. Alan B. Chmurny, Oceanix Bioscien= ce Corporation (confirmed)=0A=0AAPPLICATIONS FOR DRUG DISCOVERY=0AAdvances = in Methodology for High Throughput Solution and Solid-Phase=0ASynthesis of = Small Molecules =0ADr. Douglas Livingston, Arris Pharmaceutical Corporation= (confirmed)=0ACombinatorial Methodologies for Lead Generation and Lead Opt= imization in=0ADrug Discovery: =0ADr. Mark J. Suto, Signal Pharmaceuticals= , Inc. (confirmed)=0ACombinatorial Chemistry at Chiroscience: Design & Imp= lementation: =0ADr. John Montana, Chiroscience Ltd. (confirmed)=0AClose In= teractive Circle: Computer Assisted Drug Design and In-Depth in=0AVitro Ch= aracterization of Their Biological Activity: A Timely Way to Success? =0A= Dr. Stefan Nilsson, Karo Bio AB (confirmed)=0AAccelerated Drug Discovery Us= ing Combinatorial Chemistry: =0ADr. Stephen W. Kaldor,Lilly Research Labor= atories, Eli Lilly & Company=0A(confirmed)=0AUse of Genomics and Combinator= ial Chemistry in Inflammation and Autoimmune=0ADisease Drug Discovery: =0A= Dr. John Latham, Darwin Molecular (confirmed)=0AInterfering with HIV Regula= tory Mechanisms: From Complex Libraries and=0AFocused Arrays to Individual= Compounds with Cellular Activity: =0ADr. Eduard R. Felder, Ciba-Geigy Ltd= .. (confirmed)=0AAcquisition and Screening of Combinatorial Libraries as Pot= ential Anticancer=0AAIDS Antiviral Agents: =0ADr Jill Johnson NCI (confirm= ed)=0AStructure-Based Combinatorial Libraries to Identify a Low Nanomolar= =0AInhibitor: Ms. Ellen K. Kick, University of California, Berkeley (confi= rmed)=0ADr. John Baldwin, Pharmacopeia, Inc. (invited) =0A=0A=0A=0ACombinat= orial chemistry has now progressed to the stage where the first =0Aclinical= trials of lead small molecule drugs discovered and or optimized =0Athrough= the use of combinatorial libraries are underway. Pharmaceutical =0Aand bi= otechnology companies are responding by developing the information=0Atechno= logy and automation tools necessary to manipulate, design and record =0Athe= chemical diversity and compound results from combinatorial libraries. =0A= The program opens with by examining business issues and patent laws related= =0Ato combinatorial chemistry as well as the challenge of accessing the po= wer =0Aof genomics for target identification. The large volume of potentia= l reagents, =0Apossible reactions, and screening results involves an overwh= elming accumulation =0Aof data, which must be integrated and analysed autom= atically to take full=0Aadvantage of the power of this approach. Different= perspectives for library=0Astrategies are covered on the second day, parti= cularly by speakers from =0Acombinatorial chemistry companies. Talks focus= ing more on the application of =0Athis technology for product development a= re featured on the third day. Target =0Aapplications include autoimmune diseases, inflammation, cancer, CNS= , and HIV.=0A=0ACommercial: MLD SPS Both=0ALate= or On Site $995 $895 $1590 (save $300)=0A=0AAdademic= : MLD SPS Both=0ALate or On Site = $495 $445 $790 (save $250)=0A=0A=0ACambridge Healthtech Institute= =92s Second Annual=0ASolid Phase Synthesis: Developing Small Molecule Libr= aries=0AFebruary 6-7, 1997 * Loews Coronado Bay Resort, Coronado, CA=0A=0AC= OMBINATORIAL LIBRARY STRATEGIES=0ALibraries from Libraries: Small Heterocy= clic Molecules Derived from =0APeptides and Peptoids: =0ADr. Jean-Philippe = Meyer, Torrey Pines Institute for Molecular Studies=0A(confirmed)=0AParalle= l Synthesis Methodologies for Mixtures and Single Compounds: =0ADr. John S= teele, Pfizer Central Research (confirmed)=0ADiversity Platforms in Combina= torial Chemistry: =0ADr. Robert Armstrong, Amgen Inc. (confirmed)=0AStrate= gies Towards Solid Phase Synthesis of Small Molecules: =0ADr. Sarvajit Cha= krvarty, Scios Inc. (tentative)=0ADr. Christopher Holmes, Affymax Research = Institute (confirmed)=0ADr. George Barany, University of Minnesota (confirm= ed=0A=0ACHEMISTRY AND APPLICATIONS=0AOne-bead One-compound Combinatorial Li= brary Method in Basic Research and=0ADrug Discovery: =0ADr. Kit S. Lam, Un= iversity of Arizona (confirmed)=0AModular Design, Encoding and Logistics of= Multiple Parallel Synthesis of=0A=93Single=94 Small Molecule Compounds: = =0ADr. N. Joe Maeji, Chiron Mimotopes Pty Ltd. (confirmed)=0ASolid Phase Co= mbinatorial Chemistry: the Discovery of a Novel Series of MDR=0AReversing = Agents: =0ADr. Edmund J. Moran, Ontogen Corporation (confirmed)=0ASolid-Ph= ase Isoxazoline and Isoxazole Strategies: =0ADr. Mark J. Kurth, University= of California, Davis (confirmed)=0ADouble Combinatorial Chemistry: a H= ighly Efficient Method for Introducing=0AChemical Diversity: =0ADr. Glenn = Tong, AudA Pharmaceuticals ApS (tentative)=0ADr. Anthony Baxter, Oxford Div= ersity (invited)=0A=0AAUTOMATION=0AExtending the Limits of Automation for H= igh Throughput Synthesis: =0ADr. Mark L. Peterson, Advanced ChemTech, Inc.= (confirmed)=0AThe CombiSyn-40 Meets Organic Chemistry: =0ADr. Steven Bond= y, CombiChem Inc. (confirmed)=0ACombinatorial Chemistry and Automation: Op= en Instrument Architecture for=0AParellel Synthesis: =0ADr. David L. Juran= as, Tecan U.S., Inc. (confirmed)=0ASolid Phase Synthesis of Smll Molecule D= rug Libraries Using Second=0AGeneration 96-well Array Synthesizer: =0ADr. = Robert J. Molinari, Protogene Laboratories, Inc. (confirmed)=0AAutomated Pa= rallel Synthesis of Antitubercular Agents: =0ADr. William R. Baker, PathoG= enesis Corporation, (confirmed)=0ADr. Joel Martin, Argonaut Technologies, I= nc. (invited)=0A=0ARESINS AND LINKERS=0ASolid-Phase Organic Synthesis: A P= eptide Chemist=92s Perspective: =0ADr. Steve A. Kates, PerSeptive Biosyst= ems, Inc. (confirmed)=0ANew Polymeric Linkers and Matrices for Organic Synt= hesis: =0ADr. Kim D. Janda (confirmed)=0ABeads, Linkers, Screens and Tags = for Combinatorial Chemistry: =0ADr. Mark Bradley, University of Southhampton (confirmed)=0ANew Developments in the Field of Resins and Linke= rs: =0ADr. Aubrey J. Mendonca, Novabiochem USA (confirmed)=0ALarge Bead An= alysis, New Linkers and Cleavage Strategies: =0ADr. Michael Moore, SmithKli= ne Beecham (confirmed)=0ADr. Wolfgang Rapp, Rapp Polymere GmbH (invited)=0A= =0AThe use of solid phase synthesis for peptide and nucleic acid applicatio= ns=0Ais well established, but the experience of applying this approach for = small=0Amolecule reactions has only recently received comparable attention.= This=0Anew focus is a direct result of the effort to develop small molecu= le=0Acombinatorial libraries. Researchers are finding that a very wide ran= ge of=0Achemistries and reactions can be adapted to solid phase, although n= ew=0Alinkers and supports may be needed to gain access to as wide a range a= s=0Apossible. The development of automated equipment specifically designed= for=0Asmall molecule reactions is also having a significant impact, both o= n=0Aprocess development and the creation of such libraries. =0A=0ACommercia= l: MLD SPS Both=0ALate or On Site = $995 $895 $1590 (save $300)=0A=0AAdademic: M= LD SPS Both=0ALate or On Site $495 $445 $790 = (save $250)=0A=0AMOLECULAR EVOLUTION=0AAPRIL 24-25, 1997=0ACOPLEY PLAZA=0AB= OSTON, MASSACHUSETTS=0A=0A=0ANUCLEIC ACID EVOLUTION=0AIn Vivo and In Vitro = Applications of Nucleic Acid Ligands=0A Dr. Daniel W. Drolet, NeXsta= r Pharmaceuticals (confirmed)=0AMirror-Image RNA Ligands=0A Dr. Jens= P. Furste, Freie Universitst Berlin (confirmed)=0AAptamer Evolution: Pros= pects for Diagnostics and Therapeutics=0A Dr. Andrew D. Ellington, I= ndiana University (confirmed)=0ARibozymes from Random Sequences: Dr. David= Bartel, Whitehead Institute =0A and Massachusetts Institute of Tech= nology (confirmed)=0A=0AENGINEERING PROTEINS AND ANTIBODIES=0AExploiting th= e Diversity of Large Human Antibody Libraries=0A Dr. John McCafferty= , Cambridge Antibody Technology Ltd. (confirmed)=0AMolecular Evolution of P= roteins, Pathways and Viruses by DNA Shuffling=0A Dr. Willem Stemmer= , Maxygen, Inc. (confirmed)=0AIn Vitro Selection of Peptides Acting on NMDA= Glutamate Receptors=0A Dr. Min Li, John Hopkins School of Medicine = (confirmed)=0ASynthesis Based Molecular Design of Antibodies and Proteins: = =0A Dr. William D. Huse, Ixsys, Inc. (confirmed)=0A Dr. M= anuel Baca, Genentech, Inc. (confirmed)=0A=0ARESEARCH AND SELECTION USING P= HAGE DISLAY=0ACloning Novel Genes with Phage-Displayed Peptide Ligands=0A = Dr. Brian Kay, University of North Carolina at Chapel Hill (confirmed= )=0AAdenovirus Expression Systems in Conjunction with Autofluorescent Prote= ins:=0APotential Use in the Screening of Peptide Libraries=0A Dr. Lu= c Peloquin, Quantum Biotechnologies Inc. (confirmed)=0AFunctional Epitope M= apping by Negative Selection of Phage-Displayed=0ARandomized Protein Librar= ies=0A Dr. Laurent Jespers, Flanders Interuniversity Institute for B= iotechnology=0A(confirmed)=0AAutomated Affinity Based Screening Using Serial Column Chromatography=0AInterfaced with Mass = Spectrometry=0A Dr. Satish Jindal, ChemGenics Pharmaceuticals (confi= rmed)=0AUse of Combinatorially Generated Phage Displayed Ligands to Develop= =0AEngineered Microprotein Ligands for Large Scale Biotherapeutic Purificat= ion=0A Dr. John Maclennan, Dyax Corporation (confirmed)=0AIdentifica= tion of Optimal Ligands for Protein Domains Using Oriented Peptide=0ALibrar= ies=0A Dr. Zhou (Sonny) Songyang, Harvard Medical School (confirmed)= =0A=0ATHERAPEUTIC DEVELOPMENTS USING PHAGE DISPLAY=0AIdentification of Amin= o Acids Critical for the Activity of a Peptide =0AMimetic of Erythropoietin= and Discription of a Minimal Functional Epitope=0A Dr. Dana Johnson= , R.W. Johnson Pharmaceutical Research Institute (confirmed)=0ACombinatoria= l Methods and Directed Evolution Applied to Staphylococcal=0Aa-hemolysin, a= Pore-Forming Protein=0A Dr. Hagan Bayley, Worcester Foundation for = Biomedical Research (confirmed)=0AHuman Protein Display: A New System for = Discovering Drug Binding Targets=0A Dr. Allan Peng, GeneMax, Inc. (c= onfirmed)=0ANovel Approaches for Targeting Tumors and Inhibiting Metastasis= =0A Dr. Renata Pasqualini, La Jolla Cancer Research Center, The Burn= ham=0AInstitute (confirmed)=0ASampling Peptide Space for Cell-Targeti= ng Peptides=0A Dr. Stephen A. Johnston, University of Texas, Southwe= stern Medical Center,=0A(confirmed)=0ACloning Using Phage Display=0A = Dr. Bob Shopes, Tera Biotechnology Corporation (confirmed)=0AEstablishing = Site Directed Assays Using Phage Displayed Libraries of =0APeptides and Ant= ibodies=0A Dr. Arthur J. Blume, DGI BioTechnologies, L.L.C. (confirm= ed)=0A=0A=0AFrom the rapid progess of combinatorial chemistry and genetics = an interest =0Ahas been generated in the selection of random peptides from = target proteins =0Aand in investigating ligand-receptor interactions. Some= challenges that =0Awill be examined are the screening of combinatorial lib= raries for selecting =0Ahigh-affinity ligands against target molecules, fol= lowing the sequential =0Acycles of random mutagenesis and screening to dire= ct the evolution of enzymes, =0Aand developing new techniques such as phage= display for optimum peptide =0A/receptor binding. The expectation that fr= om the selection and use of phage =0Adisplay, proteins for therapeutics and= drug discovery may be developed.=0A=0AEarly registration January 24, 1997= =0AAdvance registration March 7, 1997=0A=0Aposter deadline March 21, 1997= =0A=0A=0A------------------------------------------------------------------= =0AAndrew Wallace, Ph.D, Queens University Belfast, N. Ireland (UK)=0Aa.wa= llace@qub.ac.uk http://web.qub.ac.uk/bb/awpage/wallace.html=0A From owner-repertoires@net.bio.net Thu Jan 16 22:00:00 1997 Path: biosci!qub.ac.uk!a.wallace From: a.wallace@qub.ac.uk (Andrew Wallace) Newsgroups: bionet.molecules.repertoires Subject: Royal Society/NATO postdoc program Date: 17 Jan 1997 09:34:11 -0800 Organization: Queens University Belfast Lines: 40 Sender: daemon@net.bio.net Distribution: world Message-ID: <32DFB89F.69C6@qub.ac.uk> Reply-To: a.wallace@queens-belfast.ac.uk NNTP-Posting-Host: net.bio.net If you are a postdoc from an Eastern European country, are under 40 years old and want to do non-clinical medical research in the UK for up to 12 months, then read on. I am looking for candidates from NATO cooperation countries to apply jointly with me to THE ROYAL SOCIETY/NATO POSTDOCTORAL FELLOWSHIP PROGRAMME. If we are successful, the candidates will receive an award to work in my laboratory here in the UK for up to 12 months. POSTDOCTORAL SCIENTISTS from ONLY THE FOLLOWING NATO cooperation partner countries are eligible: Albania, Armenia, Azerbaijan, Belarus, Bulgaria, Czech Republic, Estonia, Georgia, Hungary, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Poland, Romania, Russia, Slovak Republic, Slovenia, Tajikstan, Turkmenistan, Ukraine, Uzbekistan and the Former Yugoslav Republic of Macedonia. Under this programme, fellowship holders receive an award which covers living costs in the UK, together with a contribution towards travel costs and research expenses. I am particularly interested to hear from candidates in the following fields: 1. Intracellular signalling pathways. 2. Recombinant protein expression and mutagenesis. 3. Mammalian cell culture. 4. Combinatorial libraries (phage display, peptide libraries, etc.). 5. Solid-phase organic chemistry. For details of my own research interests, please consult the URL http://web.qub.ac.uk/bb/awpage/awproj.html or look at my web page. Andrew -- ================================================================== Andrew Wallace,Ph.D., Queens University Belfast, N. Ireland (UK) a.wallace@qub.ac.uk http://web.qub.ac.uk/bb/awpage/wallace.html ================================================================== From owner-repertoires@net.bio.net Thu Jan 16 22:00:00 1997 Path: biosci!daresbury!not-for-mail From: Andrew Wallace Newsgroups: bionet.molecules.repertoires Subject: EU partners call for proposals Date: 17 Jan 1997 12:17:22 -0000 Lines: 39 Sender: lpddist@mserv1.dl.ac.uk Distribution: bionet Message-ID: <5bnqki$4gb@mserv1.dl.ac.uk> Original-Sender: awallace@uk.ac.qub MIME-Version: 1.0 X-Authentication: none Read-Receipt-To: Andrew Wallace Original-To: molreps@dl.ac.uk Dear Colleagues, I am setting up an application to the EU Framework IV Biotech 2 programme for a concerted action on Phage Display and I am looking for partners from EU-EFTA member countries as well as Australia and possibly also Switzerland, Canada, South Africa, Israel, CEC and NIS countries. Groups from the USA may not participate. So far, I have received contributions from partners in Australia, Austria, Germany, France and the UK. I am particularly interested in hearing from potential partners in Ireland, Israel, Italy, Portugal, Spain and Sweden as well as East European and EU-EFTA countries. If you work in the phage display field in one of the eligible countries and are interested in collaborating to obtain travel money for attending conferences, networking, etc., (this will be a Concerted Action not a shared cost RTD proposal so no research money available, sorry) then please contact me at the address below. Andrew Wallace Centre for Peptide and Protein Engineering Queens University Belfast 97 Lisburn Road Belfast BT9 7BL, UK Tel. +44-1232-335787 Fax. +44-1232-236505 a.wallace@qub.ac.uk Andrew ----------------------------------------------------------------- Andrew Wallace, Ph.D, Queens University Belfast, N. Ireland (UK) a.wallace@qub.ac.uk http://web.qub.ac.uk/bb/awpage/wallace.html From owner-repertoires@net.bio.net Sun Jan 19 22:00:00 1997 Path: biosci!rutgers!news.sgi.com!su-news-hub1.bbnplanet.com!news.bbnplanet.com!cpk-news-hub1.bbnplanet.com!EU.net!uknet!usenet1.news.uk.psi.net!uknet!uknet!strath-cs!queens-belfast.ac.uk!queens-belfast.ac.uk!nntp Newsgroups: bionet.molecules.repertoires Subject: Molecular Diversity Conferences Message-ID: <32E3725A.6593@qub.ac.uk> From: Andrew Wallace Date: Mon, 20 Jan 1997 13:25:47 +0000 Reply-To: a.wallace@queens-belfast.ac.uk Organization: Queens University Belfast Nntp-Posting-Host: awall.bc.qub.ac.uk X-Mailer: Mozilla 3.0 (Macintosh; I; PPC) MIME-Version: 1.0 Content-Type: text/plain; charset=iso-8859-1 Content-Transfer-Encoding: 8bit Lines: 349 The Cambridge Healthtech Institute has three upcoming conferences that would be of interest to the subscribers of molreps. I have listed below the conference program for each. If you wish to have more information please contact: Cambridge Healthtech Institute 1037 Chestnut Street Newton Upper Falls, MA 02164 Phone:617-630-1300 Fax: 617-630-1325 e-mail:chi@healthtech.com http://www.healthtech.com/conferences/ Cambridge Healthtech Institute Fourth Annual Exploiting Molecular Diversity: Small Molecule Libraries for Drug Discovery February 3-5, 1997 * Loews Coronado Bay Resort, Coronado, CA CURRENT AND FUTURE BUSINESS/COMMERCIAL APPLICATIONS Business Issues in Combinatorial Drug Discovery: Mr. David K. Stone, Cowen & Co. (confirmed) Creating Exclusively in Molecular Diversity--Patent Law: Mr. John W. Caldwell, Woodcock Washburn Kurtz Mackiewicz & Norris (confirmed) Combinatorial Chemistry Driving Biology : A High-Throughput System to Discover Lead Drugs and Drug Target Genes: Dr. Tauseef R. Butt (confirmed) Molecular Diagnostics, Molecular Phenotypes, and Therapy Targeting: Impacts on Discovery: Dr. Christopher A. Fields, National Center for Genome Resources (confirmed) High-Throughput Lead Follow-up and Explosion: The Next Step in the Drug Discovery Pipeline: Dr. Cheryl D. Garr, Panlabs, Inc. (confirmed) INFORMATICS Integrating Mixtures and Libraries into High-Throughput Screening Data Handling and Analysis: Dr. Barr E. Bauer, MDL Information Systems, Inc. (confirmed) Role of 3D Information in the Combinatorial Chemistry Process: Library Design, Analysis, and SAR: Dr. Scott D. Kahn, Molecular Simulations, Inc. (confirmed) Designing Chemical Libraries for Lead Finding and Lead Following: Dr. Allan M. Ferguson, Tripos, Inc. (confirmed) The Well Tailored Library: Beyond Mere Diversity: Dr. Eric Martin, Chiron Corporation (confirmed) Title to be Announced: Dr. Joseph Hogan, ArQule, Inc. (confirmed) LIBRARY STRATEGIES Recent Advances in the Synthesis and Screening of Small Molecule Libraries in Solution: Dr. Edward A. Wintner, MIT (confirmed) Versatility and Advantages of Random and Directed Libraries Constructed as Single Compound, Solution Phase Reactions: Dr. James Rusche, Repligen Corporation (confirmed) Combinatorial Development Profiling: Dr. Robyn A. Rourick, Bristol-Myers Squibb (confirmed) Solution Phase, Simultaneous Addition of Functionalities (SPSAF) for the Generation of Combinatorial Chemistry Libraries: Dr. P. Dan Cook, Isis Pharmaceuticals (confirmed) Encoded Combinatorial Libraries: Dr. H. Mario Geysen, Glaxo Wellcome, Inc. (confirmed) Combinatorial Chemistry: From Concept to Application as a Drug Discovery Tool: Dr. Alex Polinsky, Alanex Corp. (confirmed) Use of Reactive Fragment Structure Transformations for Automated Structure Generation and Applications to Diversity Analysis in Combinatorial Chemistry: Dr. John F. Cargill, Ontogen Corp. (confirmed) Use of a Hetero Diels-Alder Reaction to Prepare Tricyclic Quinolines: Dr. John S. Kiely, Houghten Pharmaceuticals, Inc. (confirmed) Low Diversity SMART LIBRARYô Constrained Secondary Structure Templates for the Development of Small Molecule Mimetics: Dr. Michael Kahn, Molecumetics, Inc. (confirmed) Combinatorial Genomics and Small Molecule Drug Discovery: Dr. Alan B. Chmurny, Oceanix Bioscience Corporation (confirmed) APPLICATIONS FOR DRUG DISCOVERY Advances in Methodology for High Throughput Solution and Solid-Phase Synthesis of Small Molecules Dr. Douglas Livingston, Arris Pharmaceutical Corporation (confirmed) Combinatorial Methodologies for Lead Generation and Lead Optimization in Drug Discovery: Dr. Mark J. Suto, Signal Pharmaceuticals, Inc. (confirmed) Combinatorial Chemistry at Chiroscience: Design & Implementation: Dr. John Montana, Chiroscience Ltd. (confirmed) Close Interactive Circle: Computer Assisted Drug Design and In-Depth in Vitro Characterization of Their Biological Activity: A Timely Way to Success? Dr. Stefan Nilsson, Karo Bio AB (confirmed) Accelerated Drug Discovery Using Combinatorial Chemistry: Dr. Stephen W. Kaldor,Lilly Research Laboratories, Eli Lilly & Company (confirmed) Use of Genomics and Combinatorial Chemistry in Inflammation and Autoimmune Disease Drug Discovery: Dr. John Latham, Darwin Molecular (confirmed) Interfering with HIV Regulatory Mechanisms: From Complex Libraries and Focused Arrays to Individual Compounds with Cellular Activity: Dr. Eduard R. Felder, Ciba-Geigy Ltd. (confirmed) Acquisition and Screening of Combinatorial Libraries as Potential Anticancer AIDS Antiviral Agents: Dr Jill Johnson NCI (confirmed) Structure-Based Combinatorial Libraries to Identify a Low Nanomolar Inhibitor: Ms. Ellen K. Kick, University of California, Berkeley (confirmed) Dr. John Baldwin, Pharmacopeia, Inc. (invited) Combinatorial chemistry has now progressed to the stage where the first clinical trials of lead small molecule drugs discovered and or optimized through the use of combinatorial libraries are underway. Pharmaceutical and biotechnology companies are responding by developing the information technology and automation tools necessary to manipulate, design and record the chemical diversity and compound results from combinatorial libraries. The program opens with by examining business issues and patent laws related to combinatorial chemistry as well as the challenge of accessing the power of genomics for target identification. The large volume of potential reagents, possible reactions, and screening results involves an overwhelming accumulation of data, which must be integrated and analysed automatically to take full advantage of the power of this approach. Different perspectives for library strategies are covered on the second day, particularly by speakers from combinatorial chemistry companies. Talks focusing more on the application of this technology for product development are featured on the third day. Target applications include autoimmune diseases, inflammation, cancer, CNS, and HIV. Commercial: MLD SPS Both Late or On Site $995 $895 $1590 (save $300) Adademic: MLD SPS Both Late or On Site $495 $445 $790 (save $250) Cambridge Healthtech Instituteís Second Annual Solid Phase Synthesis: Developing Small Molecule Libraries February 6-7, 1997 * Loews Coronado Bay Resort, Coronado, CA COMBINATORIAL LIBRARY STRATEGIES Libraries from Libraries: Small Heterocyclic Molecules Derived from Peptides and Peptoids: Dr. Jean-Philippe Meyer, Torrey Pines Institute for Molecular Studies (confirmed) Parallel Synthesis Methodologies for Mixtures and Single Compounds: Dr. John Steele, Pfizer Central Research (confirmed) Diversity Platforms in Combinatorial Chemistry: Dr. Robert Armstrong, Amgen Inc. (confirmed) Strategies Towards Solid Phase Synthesis of Small Molecules: Dr. Sarvajit Chakrvarty, Scios Inc. (tentative) Dr. Christopher Holmes, Affymax Research Institute (confirmed) Dr. George Barany, University of Minnesota (confirmed CHEMISTRY AND APPLICATIONS One-bead One-compound Combinatorial Library Method in Basic Research and Drug Discovery: Dr. Kit S. Lam, University of Arizona (confirmed) Modular Design, Encoding and Logistics of Multiple Parallel Synthesis of ìSingleî Small Molecule Compounds: Dr. N. Joe Maeji, Chiron Mimotopes Pty Ltd. (confirmed) Solid Phase Combinatorial Chemistry: the Discovery of a Novel Series of MDR Reversing Agents: Dr. Edmund J. Moran, Ontogen Corporation (confirmed) Solid-Phase Isoxazoline and Isoxazole Strategies: Dr. Mark J. Kurth, University of California, Davis (confirmed) Double Combinatorial Chemistry: a Highly Efficient Method for Introducing Chemical Diversity: Dr. Glenn Tong, AudA Pharmaceuticals ApS (tentative) Dr. Anthony Baxter, Oxford Diversity (invited) AUTOMATION Extending the Limits of Automation for High Throughput Synthesis: Dr. Mark L. Peterson, Advanced ChemTech, Inc. (confirmed) The CombiSyn-40 Meets Organic Chemistry: Dr. Steven Bondy, CombiChem Inc. (confirmed) Combinatorial Chemistry and Automation: Open Instrument Architecture for Parellel Synthesis: Dr. David L. Juranas, Tecan U.S., Inc. (confirmed) Solid Phase Synthesis of Smll Molecule Drug Libraries Using Second Generation 96-well Array Synthesizer: Dr. Robert J. Molinari, Protogene Laboratories, Inc. (confirmed) Automated Parallel Synthesis of Antitubercular Agents: Dr. William R. Baker, PathoGenesis Corporation, (confirmed) Dr. Joel Martin, Argonaut Technologies, Inc. (invited) RESINS AND LINKERS Solid-Phase Organic Synthesis: A Peptide Chemistís Perspective: Dr. Steve A. Kates, PerSeptive Biosystems, Inc. (confirmed) New Polymeric Linkers and Matrices for Organic Synthesis: Dr. Kim D. Janda (confirmed) Beads, Linkers, Screens and Tags for Combinatorial Chemistry: Dr. Mark Bradley, University of Southhampton (confirmed) New Developments in the Field of Resins and Linkers: Dr. Aubrey J. Mendonca, Novabiochem USA (confirmed) Large Bead Analysis, New Linkers and Cleavage Strategies: Dr. Michael Moore, SmithKline Beecham (confirmed) Dr. Wolfgang Rapp, Rapp Polymere GmbH (invited) The use of solid phase synthesis for peptide and nucleic acid applications is well established, but the experience of applying this approach for small molecule reactions has only recently received comparable attention. This new focus is a direct result of the effort to develop small molecule combinatorial libraries. Researchers are finding that a very wide range of chemistries and reactions can be adapted to solid phase, although new linkers and supports may be needed to gain access to as wide a range as possible. The development of automated equipment specifically designed for small molecule reactions is also having a significant impact, both on process development and the creation of such libraries. Commercial: MLD SPS Both Late or On Site $995 $895 $1590 (save $300) Adademic: MLD SPS Both Late or On Site $495 $445 $790 (save $250) MOLECULAR EVOLUTION APRIL 24-25, 1997 COPLEY PLAZA BOSTON, MASSACHUSETTS NUCLEIC ACID EVOLUTION In Vivo and In Vitro Applications of Nucleic Acid Ligands Dr. Daniel W. Drolet, NeXstar Pharmaceuticals (confirmed) Mirror-Image RNA Ligands Dr. Jens P. Furste, Freie Universitst Berlin (confirmed) Aptamer Evolution: Prospects for Diagnostics and Therapeutics Dr. Andrew D. Ellington, Indiana University (confirmed) Ribozymes from Random Sequences: Dr. David Bartel, Whitehead Institute and Massachusetts Institute of Technology (confirmed) ENGINEERING PROTEINS AND ANTIBODIES Exploiting the Diversity of Large Human Antibody Libraries Dr. John McCafferty, Cambridge Antibody Technology Ltd. (confirmed) Molecular Evolution of Proteins, Pathways and Viruses by DNA Shuffling Dr. Willem Stemmer, Maxygen, Inc. (confirmed) In Vitro Selection of Peptides Acting on NMDA Glutamate Receptors Dr. Min Li, John Hopkins School of Medicine (confirmed) Synthesis Based Molecular Design of Antibodies and Proteins: Dr. William D. Huse, Ixsys, Inc. (confirmed) Dr. Manuel Baca, Genentech, Inc. (confirmed) RESEARCH AND SELECTION USING PHAGE DISLAY Cloning Novel Genes with Phage-Displayed Peptide Ligands Dr. Brian Kay, University of North Carolina at Chapel Hill (confirmed) Adenovirus Expression Systems in Conjunction with Autofluorescent Proteins: Potential Use in the Screening of Peptide Libraries Dr. Luc Peloquin, Quantum Biotechnologies Inc. (confirmed) Functional Epitope Mapping by Negative Selection of Phage-Displayed Randomized Protein Libraries Dr. Laurent Jespers, Flanders Interuniversity Institute for Biotechnology (confirmed) Automated Affinity Based Screening Using Serial Column Chromatography Interfaced with Mass Spectrometry Dr. Satish Jindal, ChemGenics Pharmaceuticals (confirmed) Use of Combinatorially Generated Phage Displayed Ligands to Develop Engineered Microprotein Ligands for Large Scale Biotherapeutic Purification Dr. John Maclennan, Dyax Corporation (confirmed) Identification of Optimal Ligands for Protein Domains Using Oriented Peptide Libraries Dr. Zhou (Sonny) Songyang, Harvard Medical School (confirmed) THERAPEUTIC DEVELOPMENTS USING PHAGE DISPLAY Identification of Amino Acids Critical for the Activity of a Peptide Mimetic of Erythropoietin and Discription of a Minimal Functional Epitope Dr. Dana Johnson, R.W. Johnson Pharmaceutical Research Institute (confirmed) Combinatorial Methods and Directed Evolution Applied to Staphylococcal a-hemolysin, a Pore-Forming Protein Dr. Hagan Bayley, Worcester Foundation for Biomedical Research (confirmed) Human Protein Display: A New System for Discovering Drug Binding Targets Dr. Allan Peng, GeneMax, Inc. (confirmed) Novel Approaches for Targeting Tumors and Inhibiting Metastasis Dr. Renata Pasqualini, La Jolla Cancer Research Center, The Burnham Institute (confirmed) Sampling Peptide Space for Cell-Targeting Peptides Dr. Stephen A. Johnston, University of Texas, Southwestern Medical Center, (confirmed) Cloning Using Phage Display Dr. Bob Shopes, Tera Biotechnology Corporation (confirmed) Establishing Site Directed Assays Using Phage Displayed Libraries of Peptides and Antibodies Dr. Arthur J. Blume, DGI BioTechnologies, L.L.C. (confirmed) From the rapid progess of combinatorial chemistry and genetics an interest has been generated in the selection of random peptides from target proteins and in investigating ligand-receptor interactions. Some challenges that will be examined are the screening of combinatorial libraries for selecting high-affinity ligands against target molecules, following the sequential cycles of random mutagenesis and screening to direct the evolution of enzymes, and developing new techniques such as phage display for optimum peptide /receptor binding. The expectation that from the selection and use of phage display, proteins for therapeutics and drug discovery may be developed. Early registration January 24, 1997 Advance registration March 7, 1997 poster deadline March 21, 1997 -- ================================================================== Andrew Wallace,Ph.D., Queens University Belfast, N. Ireland (UK) a.wallace@qub.ac.uk http://web.qub.ac.uk/bb/awpage/wallace.html ================================================================== From owner-repertoires@net.bio.net Tue Jan 21 22:00:00 1997 Path: biosci!daresbury!not-for-mail From: Andrew Wallace Newsgroups: bionet.molecules.repertoires Subject: Phage Group Objectives Date: 22 Jan 1997 17:52:19 -0000 Lines: 74 Sender: lpddist@mserv1.dl.ac.uk Distribution: bionet Message-ID: <5c5k4j$7pq@mserv1.dl.ac.uk> Original-Sender: awallace@uk.ac.qub MIME-Version: 1.0 X-Authentication: none Read-Receipt-To: Andrew Wallace Original-To: molreps@dl.ac.uk There have been many enquiries about the objectives for the new Phage Group proposal, so I will re-list them here. The overall objective of this proposal is to create a network of collaborators on phage display which will run parallel to the current Phage Club. Phage Club is an EU Concerted Action project which is being funded under Biotech 2 of Framework IV. The outline objectives I have are as follows, but anything which is a new development within the existing Phage Club objectives is also welcome: 1. Display of enzymes or other proteins with novel functions on phage. 2. Development of functional tests for phage selection. 3. Selecting phage against D-amino acid targets (mirror image system) to derive D-aa or non-natural aa binders. 4. Development of libraries of intracellular antibodies. 5. Novel methods of cDNA product display (or further development of pJuFo system?). 6. Anything equivalent to the COLT system of Brian Kay or other direct cloning methods. 7. Development of non-prokaryotic display systems. 8. Information handling systems for phage libraries. The objectives under the existing Phage Club are: 1. The use of phage display to select specific antibodies or peptides which recognise proteins of medical or commercial interest. 2. Improvement of selection methods. 3. Improvement of vectors used in phage display. 4. Further development of techniques to clone & express cDNA on phage. 5. Improvements in the quality of antibodies selected. 6. Development of novel modified or constrained peptide phage libraries. 7. The use of phage display to alter the properties of proteins of medical or commercial interest. It would be useful to provide a short abstract now if possible, and the full proposal before the 15th of March 1997. If you can/want to start preparing your full contribution now, you should be ready to supply two pages of project description addressing the following headings: Name and Contact Information of partner Expertise and Former Experience Objectives Detailed Project Description Project Milestones General Contribution to the Project Links with Other Partners Scientific and Technical Staff Involved References Some of these you will not be able to write now, but if you are able to make a start on the rest then please go ahead. Keep those contributions coming in! Andrew Wallace Centre for Peptide and Protein Engineering Queens University Belfast 97 Lisburn Road Belfast BT9 7BL UK Tel. +44-1232-272089/272196 Fax. +44-1232-236505 ------------------------------------------------------------------ Andrew Wallace, Ph.D, Queens University Belfast, N. Ireland (UK) a.wallace@qub.ac.uk http://web.qub.ac.uk/bb/awpage/wallace.html From owner-repertoires@net.bio.net Sat Jan 25 22:00:00 1997 Path: biosci!daresbury!not-for-mail From: "Stansfield, Rob, HMR/US" Newsgroups: bionet.molecules.repertoires Subject: Data Management in support of Combinatorial Technologies Date: 26 Jan 1997 23:14:42 -0000 Lines: 41 Sender: lpddist@mserv1.dl.ac.uk Distribution: bionet Message-ID: <5cgoh2$i4c@mserv1.dl.ac.uk> Encoding: 41 TEXT Original-To: "'molreps'" , "'isisforum-l'" This message is being posted to multiple lists. I apologise if you receive duplicates. To: CHMINF-L, ISISFORUM-L, MOLREPS and MOL-DIVERSITY Selectide (a subsidiary of Hoechst Marion Roussel, Inc.) develops combinatorial chemistry libraries which are screened for biological activity, like many pharmaceutical and agrochemical companies today. I would be very interested in learning from other organizations with similar activity, what is being done for the basic information management in support of combinatorial technologies. This is NOT a request for methods of chemical diversity assessment, although that plays a role. What is being done to capture electronically, and make available, the organization's "knowledgebase" of combinatorial chemistry? (cf: MDL's Spore, Synopsys' SPS). What is being used for registration databases: - of reagents that are starting materials for automated synthesis? - of combinatorial libraries that are produced (and screened) as mixtures? - of multiple single compounds produced in parallel synthesis? What is being done to link databases of chemical information with robotics for automated synthesis, automated chemical analysis and automated screening? What is being done to link an electronic description of a (non-enumerated) combinatorial library to the results from screening? What are the tools of the trade (from Chemical Design, Daylight, MDL, MSI, Oxford Molecular, Oracle, Synopsys, Tripos etc. ) being used and why? If you are willing to share your thoughts, activities or intentions, please contact me either via this list or privately. Thanks, Rob ________________________________________________________ Robert F.D. Stansfield, Ph.D Manager, Systems Development, Information Systems / Research Selectide Corporation / Hoechst Marion Roussel, Inc. 1580 East Hanley Boulevard, Tucson, AZ 85737-9525, USA Tel: +1-520-544-5805 Fax: +1-520-575-8283 Internet: robstansfield@hmri.com " Every decoding is another encoding", Morris Zapp (jet-setting literary deconstructionist from Utopia University) ________________________________________________________ From owner-repertoires@net.bio.net Mon Jan 27 22:00:00 1997 Path: biosci!daresbury!not-for-mail From: "Janet Clench, Library, Tel:(39 6)91093220" Newsgroups: bionet.molecules.repertoires Subject: and now, for those who thought I'd given up and abandoned you ... Date: 28 Jan 1997 13:21:30 -0000 Lines: 700 Sender: lpddist@mserv1.dl.ac.uk Distribution: bionet Message-ID: <5ckugq$g19@mserv1.dl.ac.uk> Original-To: molreps@dl.ac.uk ********************************************************** SUBJECT: Combinatorial & Phage Libraries DATE: December 9,16,23 1996, January 6,13 1997 ********************************************************** Journal of Chemical Information and Computer Sciences 36: 6 (NOV-DEC 1996) ZW Luo, RX Wang, LH Lai RASSE: A new method for structure-based drug design 1187-1194 Analytical Chemistry 68: 23 (DEC 1 1996) ML Nedved, S Habibigoudarzi, B Ganem, JD Henion Characterization of benzodiazepine ''combinatorial'' chemical libraries by on-line immunoaffinity extraction, coupled column HPLC ion spray mass spectrometry tandem mass spectrometry 4228-4236 Angewandte Chemie - International Edition in English 35: 20 (NOV 4 1996) F Balkenhohl, C Vondembusschehunnefeld, A Lansky, C Zechel Combinatorial synthesis of small organic molecules 2289-2337 Angewandte Chemie - International Edition in English 35: 19 (OCT 21 1996) G Wess, K Bock, H Kleine, M Kurz, W Guba, H Hemmerle, E Lopezcalle, KH Baringhaus, H Glombik, A Enhsen, W Kramer The design and synthesis of a scaffold for combinatorial chemistry based on bile acid 2222-2224 Pure and Applied Chemistry 68: 11 (NOV 1996) P Kast, D Hilvert Genetic selection strategies for generating and characterizing catalysts 2017-2024 Journal of Organic Chemistry 61: 23 (NOV 15 1996) F Gosselin, M Direnzo, TH Ellis, WD Lubell Photoacoustic FTIR spectroscopy, a nondestructive method for sensitive analysis of solid- phase organic chemistry 7980-7981 Journal of Organic Chemistry 61: 23 (NOV 15 1996) DP Sutherlin, TM Stark, R Hughes, RW Armstrong Generation of C-glycoside peptide ligands for cell surface carbohydrate receptors using a four-component condensation on solid support 8350-8354 Tetrahedron Letters 37: 46 (NOV 11 1996) ME Garcia, JA Gavin, NL Deng, AA Andrievsky, TE Mallouk Combinatorial synthesis of modular chiral cyclophanes 8313-8316 Tetrahedron Letters 37: 46 (NOV 11 1996) J Nielsen, LO Lyngso Combinatorial solid-phase synthesis of balanol analogues 8439-8442 Tetrahedron Letters 37: 45 (NOV 4 1996) TY Chan, A Chen, N Allanson, R Chen, DS Liu, MJ Sofia Solid phase synthesis of peptidoglycan monomers for the generation of a combinatorial library 8097-8100 Tetrahedron Letters 37: 45 (NOV 4 1996) MA Scialdone Diisocyanates as scaffolds for combinatorial libraries. The solid-phase synthesis of bis- ureas from polymer-supported diisocyanates 8141-8144 Tetrahedron Letters 37: 45 (NOV 4 1996) JS Panek, B Zhu Synthesis of aromatic 1,2-diazines by inverse electron demand Diels-Alder reaction of polymer-supported 1,2,4,5-tetrazines 8151-8154 Tetrahedron Letters 37: 45 (NOV 4 1996) JH Vanmaarseveen, JAJ Denhartog, V Engelen, E Finner, G Visser, CG Kruse Solid phase ring-closing metathesis: Cyclization/cleavage approach towards a seven membered cycloolefin 8249-8252 Tetrahedron Letters 37: 45 (NOV 4 1996) DWPM Lowik, SJE Mulders, Y Cheng, YF Shao, RMJ Liskamp Synthetic receptors based on peptidosulfonamide peptidomimetics 8253-8256 Annual Reports in Medicinal Chemistry, Vol 31 (Series: Annual Reports in Medicinal Chemistry 31 (1996)) IC Choong, JA Ellman Solid-phase synthesis: Applications to combinatorial libraries 309-318 Annual Reports in Medicinal Chemistry, Vol 31 (Series: Annual Reports in Medicinal Chemistry 31 (1996)) JA Loo, DE Dejohn, RRO Loo, PC Andrews Application of mass spectrometry for characterizing and identifying ligands from combinatorial libraries 319-325 Journal of Biological Chemistry 271: 47 (NOV 22 1996) IM Lang, TL Chuang, CF Barbas, RR Schleef Purification of storage granule protein-23 - A novel protein identified by phage display technology and interaction with type 1 plasminogen activator inhibitor 30126-30135 Oncogene 13: 10 (NOV 21 1996) V Bottger, A Bottger, SF Howard, SM Picksley, P Chene, C Garciaecheverria, HK Hochkeppel, DP Lane Identification of novel mdm2 binding peptides by phage display 2141-2147 Bioorganic & Medicinal Chemistry Letters 6: 22 (NOV 19 1996) EJ Iorio, WC Still Macrocyclic triamines as linkers in two-armed receptors for peptides 2673-2676 Bioorganic & Medicinal Chemistry Letters 6: 22 (NOV 19 1996) K Burgess, C Godbout, W Li, K Payza A small library of peptidomimetics to systematically vary and test the effects of X(1) constraints 2761-2764 Cancer and Metastasis Reviews 15: 3 (SEP 1996) RG Vile, H Chong Immunotherapy .3. Combinatorial molecular immunotherapy - A synthesis and suggestions 351-364 Journal of Immunological Methods 198: 2 (NOV 13 1996) M Bluthner, EKF Bautz, FA Bautz Mapping of epitopes recognized by PM/Scl autoantibodies with gene-fragment phage display libraries 187-198 Virology 224: 2 (OCT 15 1996) M Diouri, GS Girouard, CM Allen, S Sircar, JE Vanlier, JM Weber New stimulation ligand of the adenovirus 2 protease 510-516 Journal of Computer - Aided Molecular Design 10: 5 (OCT 1996) A Caflisch Computational combinatorial ligand design: Application to human alpha-thrombin 372-396 Journal of Molecular Biology 264: 2 (NOV 29 1996) C Dang, SD Jayasena Oligonucleotide inhibitors of Taq DNA polymerase facilitate detection of low copy number targets by PCR 268-278 Molecular Microbiology 22: 4 (NOV 1996) SP Howard, HG Meiklejohn, D Shivak, R Jahagirdar A TonB-like protein and a novel membrane protein containing an ATP-binding cassette function together in exotoxin secretion 595-604 PCR Cloning Protocols (Series: Methods in Molecular Biology 67 (1997)) C Tuerk Using the SELEX combinatorial chemistry process to find high affinity nucleic acid ligands to target molecules 219-230 Biochimica et Biophysica Acta - Gene Structure and Expression 1309: 1-2 (NOV 11 1996) WP Chen, CM Cheng, AHJ Wang, TT Kuo Single-stranded DNA binding protein from bacteriophage cf: Characterization, gene localization and protein-ssDNA complex 147-155 Biochemical and Biophysical Research Communications 228: 2 (NOV 12 1996) NT Lin, YH Tseng The ori of filamentous phage phi Lf is located within the gene encoding the replication initiation protein 246-251 Nucleic Acids Research 24: 21 (NOV 1 1996) S Kreissig, K Schuddekopf, N Dear, T Boehm Expression of peptides encoded by exons in cloned mammalian DNA 4358-4359 Nucleic Acids Research 24: 21 (NOV 1 1996) J Light, R Maki, N Assamunt Expression cloning of cDNA by phage display selection 4367-4368 Journal of Virology 70: 12 (DEC 1996) PWHI Parren, P Fisicaro, AF Labrijn, JM Binley, WP Yang, HJ Ditzel, CF Barbas, DR Burton In vitro antigen challenge of human antibody libraries for vaccine evaluation: The human immunodeficiency virus type 1 envelope 9046-9050 Virology 225: 1 (NOV 1 1996) L Zeitlin, KJ Whaley, PP Sanna, TR Moench, R Bastidas, A Delogu, RA Williamson, DR Burton, RA Cone Topically applied human recombinant monoclonal IgG(1) antibody and its Fab and F(ab')(2) fragments protect mice from vaginal transmission of HSV-2 213-215 Drug Discovery Today 1: 11 (NOV 1996) J Nielsen Combinatorial chemistry and automation 458-460 Drug Discovery Today 1: 11 (NOV 1996) N Terrett Combinatorial chemistry - Antifungal analogues 493-494 Journal of Computational Biology 3: 3 (FAL 1996) E Knill, A Schliep, DC Torney Interpretation of pooling experiments using the Markov chain Monte Carlo method 395-406 Chemistry & Biology 3: 10 (OCT 1996) TW Muir, PE Dawson, MC Fitzgerald, SBH Kent Probing the chemical basis of binding activity in an SH3 domain by protein signature analysis 817-825 FEMS Microbiology Letters 145: 1 (NOV 15 1996) S Kar, RK Ghosh, AN Ghosh, A Ghosh Integration of the DNA of a novel filamentous bacteriophage VSK from Vibrio cholerae 0139 into the host chromosomal DNA 17-22 Journal of Bacteriology 178: 22 (NOV 1996) SW Ramer, D Bieber, GK Schoolnik BfpB, an outer membrane lipoprotein required for the biogenesis of bundle-forming pili in enteropathogenic Escherichia coli 6555-6563 Gene 176: 1-2 (OCT 17 1996) X Carbonell, A Villaverde Peptide display on functional tailspike protein of bacteriophage P22 225-229 Gene 178: 1-2 (OCT 31 1996) A Krebber, J Burmester, A Pluckthun Inclusion of an upstream transcriptional terminator in phage display vectors abolishes background expression of toxic fusions with coat protein g3p 71-74 Proceedings of the National Academy of Sciences of the United States of America 93: 23 (NOV 12 1996) EJ Licitra, JO Liu A three-hybrid system for detecting small ligand-protein receptor interactions 12817-12821 Schultz, J.S.; Schultz, J.S. The combinatorial library: A multifunctional resource Biotechnology Progress 12: 6 (NOV-DEC 1996) 729-743 Jette, D.C.; Kreutz, F.T.; Malcolm, B.A.; Wishart, D.S.; Noujaim, A.A.; Suresh, M.R. Epitope mapping of prostate-specific antigen with monoclonal antibodies Clinical Chemistry 42: 12 (DEC 1996) 1961-1969 Gething, M.J. Molecular chaperones: Clasping the prize Current Biology 6: 12 (DEC 1996) 1573-1576 Samuelsson, A.; Yari, F.; Hinkula, J.; Ersoy, O.; Norrby, E.; Persson, M.A.A. Human antibodies from phage libraries: Neutralizing activity against human immunodeficiency virus type 1 equally improved after expression as Fab and IgG in mammalian cells European Journal of Immunology 26: 12 (DEC 1996) 3029-3034 Rotella, D.P. Solid phase synthesis of olefin and hydroxyethylene peptidomimetics Journal of the American Chemical Society 118: 48 (DEC 4 1996) 12246-12247 Brown, B.B.; Wagner, D.S.; Geysen, H.M. A single-bead decode strategy using electrospray ionization mass spectrometry and a new photolabile linker: 3-Amino-3-(2-nitrophenyl)propionic acid Molecular Diversity 1: 1 (SEP 1995) 4-12 Meyers, H.V.; Dilley, G.J.; Durgin, T.L.; Powers, T.S.; Winssinger, N.A.; Zhu, H.; Pavia, M.R. Multiple simultaneous synthesis of phenolic libraries Molecular Diversity 1: 1 (SEP 1995) 13-20 Pinilla, C.; Buencamino, J.; Appel, J.R.; Hopp, T.P.; Houghten, R.A. Mapping the detailed specificity of a calcium-dependent monoclonal antibody through the use of soluble positional scanning combinatorial libraries: Identification of potent calcium- independent antigens Molecular Diversity 1: 1 (SEP 1995) 21-28 LaBean, T.H.; Kauffman, S.A.; Butt, T.R. Libraries of random-sequence polypeptides produced with high yield as carboxy-terminal fusions with ubiquitin Molecular Diversity 1: 1 (SEP 1995) 29-38 Haaparanta, T.; Huse, W.D. A combinatorial method for constructing libraries of long peptides displayed by filamentous phage Molecular Diversity 1: 1 (SEP 1995) 39-52 Levitan, B.; Kauffman, S. Adaptive walks with noisy fitness measurements Molecular Diversity 1: 1 (SEP 1995) 53-68 Lam, K.S. International Conference on Combinatorial Library Methods for Basic Research and Drug Discovery Molecular Diversity 2: 1-2 (OCT 1996) 1-1 Smith, G.P.; Yu, J.N. In search of dark horses: Affinity maturation of phage-displaced ligands Molecular Diversity 2: 1-2 (OCT 1996) 2-4 Hoffman, N.G.; Sparks, A.B.; Carter, J.M.; Kay, B.K. Binding properties of SH3 peptide ligands identified from phage-displayed random peptide libraries Molecular Diversity 2: 1-2 (OCT 1996) 5-12 Peletskaya, E.N.; Glinsky, G.; Deutscher, S.L.; Quinn, T.P. Identification of peptide sequences that bind the Thomsen-Friedenreich cancer-associated glycoantigen from bacteriophage peptide display libraries Molecular Diversity 2: 1-2 (OCT 1996) 13-18 Pennington, M.E.; Lam, K.S.; Cress, A.E. The use of a combinatorial library method to isolate human tumor cell adhesion peptides Molecular Diversity 2: 1-2 (OCT 1996) 19-28 Appel, J.R.; Buencamino, J.; Houghten, R.A.; Pinilla, C. Exploring antibody polyspecificity using synthetic combinatorial libraries Molecular Diversity 2: 1-2 (OCT 1996) 29-34 Nestler, H.P. Sequence-selective nonmacrocyclic two-armed receptors for peptides Molecular Diversity 2: 1-2 (OCT 1996) 35-40 Houghten, R.A.; Blondelle, S.E.; Dooley, C.T.; Dorner, B.; Eichler, J.; Ostresh, J.M. Libraries from libraries: Generation and comparison of screening profiles Molecular Diversity 2: 1-2 (OCT 1996) 41-45 Hruby, V.J.; Shenderovich, M.; Lam, K.S.; Lebl, M. Design considerations and computer modeling related to the development of molecular scaffolds and peptide mimetics for combinatorial chemistry Molecular Diversity 2: 1-2 (OCT 1996) 46-56 Salmon, S.E.; LiuStevens, R.H.; Zhao, Y.; Lebl, M.; Krchnak, V.; Wertman, K.; Sepetov, N.; Lam, K.S. High-volume cellular screening for anticancer agents with combinatorial chemical libraries: A new methodology Molecular Diversity 2: 1-2 (OCT 1996) 57-63 Hassan, M.; Bielawski, J.P.; Hempel, J.C.; Waldman, M. Optimization and visualization of molecular diversity of combinatorial libraries Molecular Diversity 2: 1-2 (OCT 1996) 64-74 Stankova, M.; Lebl, M. Library generation through successive substitution of trichlorotriazine Molecular Diversity 2: 1-2 (OCT 1996) 75-80 Baldwin, J.J. Design, synthesis and use of binary encoded synthetic chemical libraries Molecular Diversity 2: 1-2 (OCT 1996) 81-88 Vandersteen, A.M.; Han, H.; Janda, K.D. Liquid-phase combinatorial synthesis: In search of small-molecule enzyme mimics Molecular Diversity 2: 1-2 (OCT 1996) 89-96 Goodfellow, V.S.; Laudeman, C.P.; Gerrity, J.I.; Burkard, M.; Strobel, E.; Zuzack, J.S.; McLeod, D.A. Rationally designed non-peptides: Variously substituted piperazine libraries for the discovery of bradykinin antagonists and other G-protein-coupled receptor ligands Molecular Diversity 2: 1-2 (OCT 1996) 97-102 Ley, A.C.; Markland, W.; Ladner, R.C. Obtaining a family of high-affinity, high-specificity protein inhibitors of plasmin and plasma kallikrein Molecular Diversity 2: 1-2 (OCT 1996) 119-124 Quarrell, R.; Claridge, T.D.W.; Weaver, G.W.; Lowe, G. Structure and properties of TentaGel resin beads: Implications for combinatorial library chemistry Molecular Diversity 1: 4 (AUG 1996) 223-232 Eichler, J.; Lucka, A.W.; Pinilla, C.; Houghten, R.A. Novel alpha-glucosidase inhibitors identified using multiple cyclic peptide combinatorial libraries Molecular Diversity 1: 4 (AUG 1996) 233-240 Caparon, M.H.; DeCiechi, P.A.; Devine, C.S.; Olins, P.O.; Lee, S.C. Analysis of novel streptavidin-binding peptides, identified using a phage display library, shows that amino acids external to a perfectly conserved consensus sequence and to the presented peptides contribute to binding Molecular Diversity 1: 4 (AUG 1996) 241-246 Kibbey, C.E. Quantitation of combinatorial libraries of small organic molecules by normal-phase HPLC with evaporative light-scattering detection Molecular Diversity 1: 4 (AUG 1996) 247-258 Pierce, H.H.; Adey, N.; Kay, B.K. Identification of cyclized calmodulin antagonists from a phage display random peptide library Molecular Diversity 1: 4 (AUG 1996) 259-265 Parlow, J.J.; Normansell, J.E. Discovery of a herbicidal lead using polymer-bound activated esters in generating a combinatorial library of amides and esters Molecular Diversity 1: 4 (AUG 1996) 266-269 Hardin, J.H.; Smietana, F.R. Automating combinatorial chemistry: A primer on benchtop robotic systems Molecular Diversity 1: 4 (AUG 1996) 270-274 Krchnak, V.; Weichsel, A.S.; Cabel, D.; Flegelova, Z.; Lebl, M. Structurally homogeneous and heterogeneous synthetic combinatorial libraries Molecular Diversity 1: 3 (MAY 1996) 149-164 McConnell, S.J.; Uveges, A.J.; Fowlkes, D.M.; Spinella, D.G. Construction and screening of M13 phage libraries displaying long random peptides Molecular Diversity 1: 3 (MAY 1996) 165-176 Krchnak, V.; Weichsel, A.S.; Issakova, O.; Lam, K.S.; Lebl, M. Bifunctional scaffolds as templates for synthetic combinatorial libraries Molecular Diversity 1: 3 (MAY 1996) 177-182 Krchnak, V.; Lebl, M. Synthetic library techniques: Subjective (biased and generic) thoughts and views Molecular Diversity 1: 3 (MAY 1996) 193-216 DeCiechi, P.A.; Devine, C.S.; Lee, S.C.; Howard, S.C.; Olins, P.O.; Caparon, M.H. Utilization of multiple phage display libraries for the identification of dissimilar peptide motifs that bind to a B7-1 monoclonal antibody Molecular Diversity 1: 2 (FEB 1996) 79-86 Slootstra, J.W.; Puijk, W.C.; Ligtvoet, G.J.; Langeveld, J.P.M.; Meloen, R.H. Structural aspects of antibody-antigen interaction revealed through small random peptide libraries Molecular Diversity 1: 2 (FEB 1996) 87-96 Patten, P.A.; Sonoda, T.; Davis, M.M. Directed evolution studies with combinatorial libraries of T4 lysozyme mutants Molecular Diversity 1: 2 (FEB 1996) 97-108 Felder, E.R.; Heizmann, G.; Matthews, I.T.; Rink, H.; Spieser, E. A new combination of protecting groups and links for encoded synthetic libraries suited for consecutive tests on the solid phase and in solution Molecular Diversity 1: 2 (FEB 1996) 109-112 Dankwardt, S.M.; Phan, T.M.; Krstenansky, J.L. Combinatorial synthesis of small-molecule libraries using 3-amino-5-hydroxybenzoic acid Molecular Diversity 1: 2 (FEB 1996) 113-120 Fu, H.; Khosla, C. Antibiotic activity of polyketide products derived from combinatorial biosynthesis: Implications for directed evolution Molecular Diversity 1: 2 (FEB 1996) 121-124 Scott, B.O.; Siegmund, A.C.; Marlowe, C.K.; Pei, Y.Z.; Spear, K.L. Solid phase organic synthesis (SPOS): A novel route to diketopiperazines and diketomorpholines Molecular Diversity 1: 2 (FEB 1996) 125-134 Kay, B.K.; Paul, J.I. High-throughput screening strategies to identify inhibitors of protein-protein interactions Molecular Diversity 1: 2 (FEB 1996) 139-140 Demangel, C.; Lafaye, P.; Mazie, J.C. Reproducing the immune response against the Plasmodium vivax merozoite surface protein 1 with mimotopes selected from a phage-displayed peptide library Molecular Immunology 33: 11-12 (AUG 1996) 909-916 Dorey, E. Nobel discovery in combinatorial chemistry Nature Biotechnology 14: 13 (DEC 1996) 1643-1643 Lockhart, D.J.; Dong, H.L.; Byrne, M.C.; Follettie, M.T.; Gallo, M.V.; Chee, M.S.; Mittmann, M.; Wang, C.W.; Kobayashi, M.; Horton, H.; Brown, E.L. Expression monitoring by hybridization to high-density oligonucleotide arrays Nature Biotechnology 14: 13 (DEC 1996) 1675-1680 Ueda, H.; Tsumoto, K.; Kubota, K.; Suzuki, E.; Nagamune, T.; Nishimura, H.; Schueler, P.A.; Winter, G.; Kumagai, I.; Mahoney, W.C. Open sandwich ELISA: A novel immunoassay based on the interchain interaction of antibody variable region Nature Biotechnology 14: 13 (DEC 1996) 1714-1718 Lorimer, I.A.J.; KepplerHafkemeyer, A.; Beers, R.A.; Pegram, C.N.; Bigner, D.D.; Pastan, I. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display Proceedings of the National Academy of Sciences of the United States of America 93: 25 (DEC 10 1996) 14815-14820 Parsons, H.L.; Earnshaw, J.C.; Wilton, J.; Johnson, K.S.; Schueler, P.A.; Mahoney, W.; McCafferty, J. Directing phage selections towards specific epitopes Protein Engineering 9: 11 (NOV 1996) 1043-1049 Stump, M.D.; Steege, D.A. Functional analysis of filamentous phage f1 mRNA processing sites RNA - A Publication of the RNA Society 2: 12 (DEC 1996) 1286-1294 Hollinshead, S.P. Stereoselective synthesis of highly functionalised pyrrolidines via 1,3-dipolar cycloaddition reactions on a solid support. Tetrahedron Letters 37: 51 (DEC 16 1996) 9157-9160 Kobayashi, S.; Nagayama, S.; Busujima, T. Polymer scandium-catalyzed three-component reactions leading to diverse amino ketone, amino ester, and amino nitrile derivatives Tetrahedron Letters 37: 51 (DEC 16 1996) 9221-9224 Jung, G. Natural peptide libraries of microbial and mammalian origin Combinatorial Peptide and Nonpeptide Libraries (1996) 1-18 BeckSickinger, A.G.; Jung, G. From multiple peptide synthesis to peptide libraries Combinatorial Peptide and Nonpeptide Libraries (1996) 79-109 Furka, A. Chemical synthesis of peptide libraries Combinatorial Peptide and Nonpeptide Libraries (1996) 111-137 Pinilla, C.; Appel, J.; Dooley, C.; Blondelle, S.; Eichler, J.; Dorner, B.; Ostresh, J.; Houghten, R.A. The versatility of nonsupport-bound combinatorial libraries Combinatorial Peptide and Nonpeptide Libraries (1996) 139-171 Lam, K.S.; Lebl, M. Combinatorial library based on the one-bead one-compound concept Combinatorial Peptide and Nonpeptide Libraries (1996) 173-201 Wiesmuller, K.H.; Feiertag, S.; Fleckenstein, B.; Kienle, S.; Stoll, D.; Herrmann, M.; Jung, G. Peptide and cyclopeptide libraries: Automated synthesis, analysis and receptor binding assays Combinatorial Peptide and Nonpeptide Libraries (1996) 203-246 Metzger, J.W.; Wiesmuller, K.H.; Kienle, S.; Brunjes, J.; Jung, G. Mass spectrometric analysis of peptide libraries Combinatorial Peptide and Nonpeptide Libraries (1996) 247-285 Keilholz, W.; Stevanovic, S. Multiple sequence analysis of natural and synthetic peptide libraries Combinatorial Peptide and Nonpeptide Libraries (1996) 287-301 Rodda, S.; Tribbick, G.; Geysen, M. Epitope mapping with the use of peptide libraries Combinatorial Peptide and Nonpeptide Libraries (1996) 303-326 Spatola, A.F.; Romanovskis, P. Cyclic peptide libraries: Recent developments Combinatorial Peptide and Nonpeptide Libraries (1996) 327-347 Udaka, K.; Wiesmuller, K.H.; Kienle, S.; Feiertag, S.; Jung, G.; Walden, P. Random peptide libraries as tools in basic and applied immunology Combinatorial Peptide and Nonpeptide Libraries (1996) 349-362 Frank, R.; Hoffmann, S.; Kiess, M.; Lahmann, H.; Tegge, W.; Behn, C.; Gausepohl, H. Combinatorial synthesis on membrane supports by the SPOT technique: Imaging peptide sequence and shape space Combinatorial Peptide and Nonpeptide Libraries (1996) 363-386 Brunjes, J.; Metzger, J.W.; Jung, G. QMass: A computer program for the analysis of mass spectra of peptide libraries Combinatorial Peptide and Nonpeptide Libraries (1996) 511-520 Stopar, D.; Spruijt, R.B.; Wolfs, C.J.A.M.; Hemminga, M.A. Local dynamics of the M13 major coat protein in different membrane-mimicking systems Biochemistry 35: 48 (DEC 3 1996) 15467-15473 Yao, Z.J.; Chan, M.C.; Kao, M.C.C.; Chung, M.C.M. Linear epitopes of sperm whale myoglobin identified by polyclonal antibody screening of random peptide library International Journal of Peptide and Protein Research 48: 5 (NOV 1996) 477-485 Kaspari, A.; Schierhorn, A.; Schutkowski, M. Solid-phase synthesis of peptide-4-nitroanilides International Journal of Peptide and Protein Research 48: 5 (NOV 1996) 486-494 Arnold, G.F.; Resnick, D.A.; Smith, A.D.; Geisler, S.C.; Holmes, A.K.; Arnold, E. Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes Intervirology 39: 1-2 (JAN-APR 1996) 72-78 Wallace, A.; Koblan, K.S.; Hamilton, K.; MarquisOmer, D.J.; Miller, P.J.; Mosser, S.D.; Omer, C.A.; Schaber, M.D.; Cortese, R.; Oliff, A.; Gibbs, J.B.; Pessi, A. Selection of potent inhibitors of farnesyl-protein transferase from a synthetic tetrapeptide combinatorial library Journal of Biological Chemistry 271: 49 (DEC 6 1996) 31306-31311 Welply, J.K.; Steininger, C.N.; Caparon, M.; Michener, M.L.; Howard, S.C.; Pegg, L.E.; Meyer, D.M.; DeCiechi, P.A.; Devine, C.S.; Casperson, G.F. A peptide isolated by phage display binds to ICAM-1 and inhibits binding to LFA-1 Proteins - Structure Function and Genetics 26: 3 (NOV 1996) 262-270 Qi, J.; Fang, R.; Zhou, H.; Li, W.; Shen, J.C. A preliminary study on the possibility of screening small peptide in peptide library Chemical Journal of Chinese Universities - Chinese 17: 11 (NOV 1996) 1738-1741 Chucholowski, A.; Masquelin, T.; Obrecht, D.; Stadlwieser, J.; Villalgordo, J.M. Novel solution- and solid-phase strategies for the parallel and combinatorial synthesis of small-molecular-weight compound libraries Chimia 50: 11 (NOV 1996) 525-530 Winger, B.E.; Campana, J.E. Characterization of combinatorial peptide libraries by electrospray ionization Fourier transform mass spectrometry Rapid Communications in Mass Spectrometry 10: 14 (1996) 1811-1813 Nawrocki, J.P.; Wigger, M.; Watson, C.H.; Hayes, T.W.; Senko, M.W.; Benner, S.A.; Eyler, J.R. Analysis of combinatorial libraries using electrospray Fourier transform ion cyclotron resonance mass spectrometry Rapid Communications in Mass Spectrometry 10: 14 (1996) 1860-1864 Tietze, L.F.; Hippe, T.; Steinmetz, A. Solid-phase three-component domino reactions: Combinatorial approach to substituted 3,4- dihydro-2H-pyrans Synlett : 11 (NOV 1996) 1043 Shimizu, M.; Yoshida, A.; Mikami, K. Carbonyl-ene approach to the asymmetric synthesis of 2-keto-3-deoxy-D-gluconic acid (KDG): A combinatorial sequence using sharpless epoxidation Synlett : 11 (NOV 1996) 1112 From owner-repertoires@net.bio.net Mon Jan 27 22:00:00 1997 Path: biosci!internet!biosci!not-for-mail From: biohelp (BIOSCI Administrator) Newsgroups: bionet.molecules.repertoires Subject: BIOSCI/bionet miniFAQ & Fundraiser Date: 28 Jan 1997 02:00:11 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 239 Sender: daemon@net.bio.net Distribution: world Message-ID: <199701281000.CAA07091@net.bio.net> NNTP-Posting-Host: net.bio.net (LAST REVISION: 30-JUL-95) This BIOSCI "miniFAQ" is designed to answer the questions that come up the *most frequently*. The main BIOSCI FAQ (Frequently Asked Questions) is accessible on the World Wide Web at URL http://www.bio.net/. If you can not find an answer to your question in this or other documentation, the BIOSCI technical support staff answers e-mail queries sent to biosci-help@net.bio.net We can only answer questions about the use of the newsgroups and mailing lists. We unfortunately do not have the staff to do Internet information searches or answer scientific questions. Please post those to the appropriate BIOSCI/bionet newsgroups. Contents: -------- 0) BIOSCI NEEDS YOUR SUPPORT!! 1) Using the WWW to access the BIOSCI/bionet newsgroups. 2) What to do about "spams," i.e., junk mail, ads, etc. 3) Examples of subscribing and unsubscribing to the mailing lists. 4) The BIOSCI user address and research interest directory. 0) BIOSCI NEEDS YOUR SUPPORT!! ------------------------------ BIOSCI's government funding has been expended, and we are now operating solely from advertising revenue that we have raised from our Web site at http://www.bio.net/. We need just a few minutes of your time to help us serve you. You can do two important things which will take very little time for you individually and will immensely help us continue to help you. First, please use our WWW system at http://www.bio.net/ to access the archives. You can post or reply to messages via your Web browser as described in item #1 below. Your usage helps attract sponsors. If you contact any of our sponsors, please be sure to thank them for supporting BIOSCI. It is critical for them to get this feedback if they are to continue their sponsorship for the long term. Second, if you work for a company or organization that provides products or services of interest to the biology community, please pass this message on to your marketing or marketing communications department or other appropriate group. Please ask them to help support BIOSCI by sponsoring our Web site and explain the uses and benefits of the system to the biology community. If they are interested, they can then contact us for further information at our tech support address, biosci-help@net.bio.net. 1) Using the WWW to access the BIOSCI/bionet newsgroups. -------------------------------------------------------- As of 10 December 1995, all BIOSCI/bionet full newsgroups are accessible through the World Wide Web (WWW) at URL http://www.bio.net. One can read and reply publicly or privately to both recent postings and archived messages through one's Web browser if it is configured properly to send e-mail. Each newsgroup is equipped with its own WAIS index. The main BIOSCI home page also has access to the BIO-JOURNALS Table of Contents database WAIS index and the BIOSCI user address database described in another item further below. 2) What to do about "spams," i.e., junk mail, ads, etc. ------------------------------------------------------- BIOSCI is a set of parallel USENET newsgroups (the "bionet" groups), mailing lists, and a hypermail archive at URL http://www.bio.net/. The same postings are distributed on all media (except for a small number of mailing-list-only groups at net.bio.net). Unfortunately it is becoming a despicable practice on the Internet (by a few people out to make a fast buck) to do automated mass postings to thousands of newsgroups and mailing lists. These attempts to grab free advertising are refered to as "spams" in the usual, somewhat boneheaded, net terminology. USENET is more susceptible to this practice, and many spams originate on the USENET groups and then are passed on to the mailing lists. However, spammers also get lists of mailing addresses and hit these too, so neither medium is immune. What should you do personally if you get junk mail? --------------------------------------------------- Just delete it and move on without reading it further. Filing a protest is becoming increasingly useless because spammers are often disguising the addresses where the messages are sent from. Unless you really understand Internet mail systems, your attempt at protest by sending replies to the message will often end up being sent to the address of an innocent person that the spammer is victimizing. What can BIOSCI/bionet do to protect its newsgroups? ---------------------------------------------------- The only solution currently available is to moderate the newsgroup. If this newsgroup is already moderated, then you are in good shape. Moderation protects the USENET distribution from about 95% of the spams that are being sent to date and protects the mailing lists completely. Moderation means, however, that someone has to take the time to review each message before it goes out. We have set up software here that simply allows the moderator to forward to an address at net.bio.net messages that (s)he wishes to have distributed. This takes no more time than that needed to read the message and pass it on, say about 1 min. per message. Most newsgroups currently have a discussion leader who is responsible for their newsgroup. The discussions leaders and their e-mail addresses are listed in the BIOSCI Information Sheet which is available on the Web at http://www.bio.net/. If a newsgroup is being hit with too many junk postings, please contact the discussion leader for that group and see if there is interest in moderating the group. Please do not assume that by simply posting a complaint to the newsgroup itself, anyone on the BIOSCI staff will act on your complaint. With close to 100 newsgroups to run, the BIOSCI staff has to rely on the discussion leaders of each newsgroup to report problems directly to us at biosci-help@net.bio.net. We will moderate any of our newsgroups if the discussion leader tells us that the readership of the group wishes to do so and if a moderator is willing to do the work. For most BIOSCI/bionet groups, this entails only a few minutes of work each day. Moderating a newsgroup will resolve probably 95% of the junk postings on the USENET distribution. Unfortunately there are easy ways for determined spammers to override the moderation mechanism on USENET, but we can protect our e-mail subscribers from unwanted postings if the newsgroup is moderated. You can also access our newsgroups over the WWW at URL http://www.bio.net. While this Web interface will not stop spammers from trying to post to the groups, this will give you yet another way, besides using USENET news, to keep the junk out of your personal mail files. For those of you with local USENET news systems, the Web interface will also give you faster access to new newsgroups and recent postings. 3) Examples of subscribing and unsubscribing to the mailing lists. ------------------------------------------------------------------ PLEASE NOTE: The BIOSCI management does NOT act on subscription/unsubscription requests that are posted improperly to the newsgroups and mailing lists. People who do this only bother everyone on the lists to no avail. Please be sure to follow the proper procedures below. Gory details are in the BIOSCI Information sheets on the Web at http://www.bio.net. Below we give an example utilizing the METHODS-AND-REAGENTS list at both of our two BIOSCI sites: Users in the Americas and Pacific Rim countries who use the BIOSCI ------------------------------------------------------------------ node at computer net.bio.net: ---------------------------- A) Determine the "listname" which is the <=8 character mail address ^^^^^^^^^^^^^ for the group. These can be found in the BIOSCI Info. Sheet. For the METHODS-AND-REAGENTS group the mailing address is methods@net.bio.net. The listname is the portion of the address to the left of the @ sign, i.e., "methods". The listname is used with the "subscribe" and "unsubscribe" commands illustrated below. B) Mail all commands in the body of a mail message addressed to biosci-server@net.bio.net. Do NOT send commands to the newsgroup posting addresses! Leave the Subject: line blank, any text on it will be ignored. C) In the body of your message put one or more of the following commands with an "end" command on the last line, e.g., subscribe methods unsubscribe methods end Do NOT put your e-mail address or other text on these lines. The server only allows you to cancel your subscription if the address on your mail header matches the address on our mailing list. Please ask for help at biosci-help@net.bio.net if your address has changed, e.g., if you know you are on the list but the server tells you that you are not a member. Users in Europe, Africa, and Central Asia who use the BIOSCI node at -------------------------------------------------------------------- computer daresbury.ac.uk (also known as dl.ac.uk): ------------------------------------------------- To subscribe and unsubscribe to/from the BIOSCI lists, you need to specify the full USENET newsgroup name with "bionet-news." prepended. The USENET newsgroup names are listed in the BIOSCI Information sheet on the Web at http://www.bio.net/. For the METHODS-AND-REAGENTS list the USENET newsgroup name is bionet.molbio.methds-reagnts, thus the appropriate commands are sub bionet-news.bionet.molbio.methds-reagnts unsub bionet-news.bionet.molbio.methds-reagnts These commands are included in a message addressed to mxt@dl.ac.uk, NOT to the newsgroup mailing addresses. As usual, include the text in the body of the message as text on the Subject: line is ignored. To unsubscribe from all the lists at the UK node, use unsub bionet-news Please note that if the address in the list is different than the one in your mail message header, you will not be able to unsubscribe by this method. If you have problems, please mail biosci@daresbury.ac.uk. 4) The BIOSCI user address and research interest directory. ----------------------------------------------------------- Please take this opportunity to add your name, address, and research interest information to the BIOSCI User Address Database if you have not already done so. You can fill out the address form directly through our Web page at URL http://www.bio.net/adrform.html. The address database is reindexed nightly for WWW access (the URL is http://www.bio.net/). If you are not directly on the Internet but can reach it by e-mail, please use our waismail server to access the user directory. waismail use is described above. You can also request a user address form by e-mail from biosci-help@net.bio.net. Please check your database entry from time-to-time to see if your address information is still up-to-date. Because of our limited personnel resources, we ask that you resubmit a *complete* form to revise your entry; we only replace complete entries and do not have resources to edit old forms. Sincerely, Dave Kristofferson BIOSCI/bionet Manager biosci-help@net.bio.net From owner-repertoires@net.bio.net Tue Jan 28 22:00:00 1997 Path: biosci!daresbury!not-for-mail From: Andrew Wallace Newsgroups: bionet.molecules.repertoires Subject: Job Opportunity in Biological Screening Date: 29 Jan 1997 09:01:55 -0000 Organization: Queens University Belfast Lines: 28 Sender: lpddist@mserv1.dl.ac.uk Distribution: bionet Message-ID: <5cn3m3$3i@mserv1.dl.ac.uk> Reply-To: a.wallace@queens-belfast.ac.uk MIME-Version: 1.0 Original-To: molreps@dl.ac.uk I have been asked to pass on this announcement. Please respond to the address at the foot of the message, not to me. Andrew -------------------------JOB ANNOUNCEMENT--------------------------- We seek a broadly trained Ph.D. level molecular biologist/biochemist to interact with combinatorial chemists, plant molecular biologists and bacterial geneticists in the design and implementation of screens and selections for bio- or catalyticly active compounds. The successful candidate will provide input into chemistry programs at their inception allowing a melding of assay requirements with synthetic design parameters. Moreover, we envision that the principal investigator will utilize a wide array of molecular techniques such as encoding protocols, bead technologies, phage display, aptamer amplification and immunological procedures to accomplish group objectives. Appreciation of the power of genetic selections and visual screens may lead the candidate to novel approaches for discovery of chemical leads. Please send c.v. and name of three references to: Dr. Pablo A. Scolnik DuPont Central Research P.O. BOX 80402 Wilmington, DE 19880-0402 USA From owner-repertoires@net.bio.net Tue Jan 28 22:00:00 1997 Path: biosci!daresbury!not-for-mail From: Andrew Wallace Newsgroups: bionet.molecules.repertoires Subject: Re: Phage Group Objectives Date: 29 Jan 1997 09:13:13 -0000 Lines: 48 Sender: lpddist@mserv1.dl.ac.uk Distribution: bionet Message-ID: <5cn4b9$sd@mserv1.dl.ac.uk> Original-Sender: awallace@uk.ac.qub MIME-Version: 1.0 X-Authentication: none Read-Receipt-To: Andrew Wallace Original-To: Dick-van Wassenaar Dear Dick, You could try Methods in Enzymology volume 267 "Combinatorial Chemistry" edited by John N. Abelson and published by Academic Press. I have a personal copy and it contains chapters by all the major players. There are also books by Riccardo Cortese on Combinatorial Chemistry and Brian Kay on Phage Display, unfortunately one of my PhD students has borrowed these so I do not have them here at the moment. Hope this helps, Andrew On 27 Jan 1997 07:55:56 Z Dick-van Wassenaar wrote: > > Dear Dr. Wallace > > I am turning to you as you [I think] might be able to answer my > question [that is if you are kind enough to do so], which is: > > > Can you perhaps give me the name of some good books that deal with > Combinatorial Chemistry in its widest context? > > Libraries, Screening, data handling etc. etc. > > Thanking you in advance, > > > Sincerely, > > Dick van Wassenaar > Unilever Resarch Vlaardingen > The Netherlands > > > dick-van.wassenaar@unilever.com ------------------------------------------------------------------ Andrew Wallace, Ph.D, Queens University Belfast, N. Ireland (UK) a.wallace@qub.ac.uk http://web.qub.ac.uk/bb/awpage/wallace.html From owner-repertoires@net.bio.net Wed Jan 29 22:00:00 1997 Path: biosci!MSU.OSCS.MONTANA.EDU!UMBAJJB From: UMBAJJB@MSU.OSCS.MONTANA.EDU (James Burritt) Newsgroups: bionet.molecules.repertoires Subject: Re: phage display vector Date: 30 Jan 1997 07:38:59 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 21 Sender: daemon@net.bio.net Distribution: world Message-ID: References: <32F0B843.42F5@rug.ac.be> NNTP-Posting-Host: net.bio.net For those interested: The vector M13KBst is available. It contains a kanamycin resistance gene and unique BstXI sites in the gene encoding the pIII protein. For more information, see Analytical Biochemistry, 1996, 238:1-13, or contact me. Jim Burritt Dept. of Microbiology 109 Lewis Hall Montana State University Bozeman, MT 59717 voice: 406-994-3926 fax: 406-994-4926 E-mail: umbajjb@msu.oscs.montana.edu On 30 Jan 1997 gonzalez.vandriessche@rug.ac.be wrote: > Which (commercially available) phage display vector can I use for > cloning random genomic DNA fragments and displaying the encoded > protein fragments ? > > From owner-repertoires@net.bio.net Wed Jan 29 22:00:00 1997 Path: biosci!rug.ac.be!gonzalez.vandriessche From: gonzalez.vandriessche@rug.ac.be Newsgroups: bionet.molecules.repertoires Subject: phage display vector Date: 30 Jan 1997 06:01:02 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 3 Sender: daemon@net.bio.net Distribution: world Message-ID: <32F0B843.42F5@rug.ac.be> NNTP-Posting-Host: net.bio.net Which (commercially available) phage display vector can I use for cloning random genomic DNA fragments and displaying the encoded protein fragments ?